Vanguard Fiduciary Trust
TOVX icon

Vanguard Fiduciary Trust’s Theriva Biologics TOVX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.4K Hold
241,780
– – ﹤0.01% 3832
2026
Q1 		$47.4K Buy
+241,780
New +$47.7K ﹤0.01% 3835

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Vanguard Fiduciary Trust's TOVX Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Theriva Biologics (TOVX) position steady in Q2 2026 at 241,780 shares worth $60.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3832.

Vanguard Fiduciary Trust first reported a position in TOVX in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Vanguard Fiduciary Trust held 241,780 shares of Theriva Biologics worth $60.4K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Theriva Biologics share count unchanged in Q2 2026.
  • Theriva Biologics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3832 holding.
  • Vanguard Fiduciary Trust first reported a position in Theriva Biologics in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.